Bora Pharmaceuticals Acquires Eden Biologics' CDMO Assets

Article

Will be investing up to $100 million to expand presence in Taiwan

Bora Pharmaceuticals, a contract development and manufacturing organization (CDMO), has established Bora Biologics Co., Ltd., a CDMO platform for biologics. Investors such as Taishin Healthcare Limited Partnership and Tanvex BioPharma Founder Dr. Allen Chao will be supporting the new endeavor. Further, as part of its 5-year growth plan, Bora noted that it will initially be investing $50 million—and up to $100 million—in the acquisition of Eden Biologics’ CDMO assets in Taiwan.

With the Eden deal, Bora can build a presence in the biological macromolecules and cell and gene therapy markets, and position the organization to expand its service offering to their clients supporting new and innovative drug development.

Bora will also have access to biopharma technologies related to the development of cell lines for the production of protein drugs, the development and analysis of upstream and downstream processes, along with the establishment of quality control and inspection specifications, as well as cell bank generation.

“The addition of the CDMO facilities, state-of-the-art equipment, and the expertise of the highly qualified team gives Bora Biologics the ability to develop and continue with our clients as they progress to commercialization,” says Simon Chen, Bora vice president.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.